Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Xenetic Biosciences, Inc. shared encouraging preclinical results for the co-administration of DNase I with CAR T cells in a murine model of melanoma lung metastasis. Presented at the AACR Special Conference, these findings support the use of DNase I as an adjunct to enhance CAR T cell therapy effectiveness in treating cancer. The study demonstrated that DNase I complements CAR T cells by reducing metastatic tumor burden and prolonging survival. The co-therapy appears to increase the infiltration of CAR T cells into tumors while lowering immune suppression. The results underscore the potential of this combination therapy in addressing unmet needs in solid tumor treatments.